Case Study Corner: LNP Formulation

Your biggest challenges inspire us. That's why Emergent supports innovative drug makers that make the seemingly impossible possible. In our latest blog series, Case Study Corner, discover how we've helped our clients overcome their biggest challenges during the development and manufacturing process.

Summary: A mid size biotech company partnered with Emergent to characterize a multi-step lipid nanoparticle formulation process for a Phase III mRNA-LNP vaccine.

Download the Full Case Study

20211111-EBSI_Gaithersburg-0047-of-0052_9538NIKON Z 7-RS


How CDMOs Can Support Nanoparticles for Gene Therapy, Immuno-Oncology and Vaccines

Nanoparticles have experienced increasing demand in recent years in biopharmaceutical formulations, owing to their utility for...


Streamlining Your Process Development Journey to GMP Manufacturing

Many CDMOs specialize in certain parts of the drug development lifecycle. Meanwhile, integrated turn-key offerings that support...


Benefits of RABS and Isolator Technology in a Changing Regulatory Landscape

Mitigating risk is a key consideration for biopharmaceutical companies when planning their clinical trial material and/or drug...